Pinorubin (pirarubicin) / Sanofi - LARVOL DELTA

Germinal center B-cell diffuse large B-cell lymphoma presenting as a chin mass: a case report. (PubMed, Ann Med Surg (Lond)) - "The patient received six cycles of rituximab, cyclophosphamide, pirarubicin, vincristine, and prednisolone chemotherapy, resulting in a significant reduction in lesion size and metabolic activity. Comprehensive evaluation, including imaging and immunohistochemistry, is critical for timely diagnosis and effective treatment. Further research is needed to understand unusual immunophenotypes and progression pathways in DLBCL."

Journal • B Cell Lymphoma • Cardiovascular • Diabetes • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hypertension • Infectious Disease • Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma • Oncology • Pain • Type 2 Diabetes Mellitus

Predictors of skeletal muscle loss during first-line therapy in diffuse large B-cell lymphoma: the Glasgow Prognostic Score. (PubMed, BMJ Support Palliat Care) - "Pretreatment GPS may serve as a surrogate marker for SMM loss risk during first-line chemotherapy in elderly patients with DLBCL. Inflammation, malnutrition, reduced physical activity and poor PS may all contribute to SMM loss. Early exercise and nutritional interventions should be considered for patients with high GPS."

Journal • B Cell Lymphoma • Cachexia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Anti-PD-1 Antibody (Tislelizumab) Combined with R-CHOP for the Treatment of Previously Untreated Primary Mediastinal B-Cell Lymphoma: A Prospective Phase II Study (ASH 2023) - P2 | "Eligible patients received 6 cycles of Tislelizumab (200 mg D1), Rituximab (375 mg/m 2 D1), Cyclophosphamide (750 mg/m 2 D2), Pirarubicin (50 mg/m 2 D2), Vincristine (1. 4 mg/m 2, maximum dose 2 mg, D2), Prednisone (100 mg/d D2-6), every 21 days for 1 cycle... Tislelizumab combined with R-CHOP for the treatment of previously untreated PMBCL had good efficacy and sustained response with low toxicity. Longer follow-up is required to access the survival benefit of this regimen. Figure 1: Disease Remission in the Included Patients"

Clinical • IO biomarker • P2 data • B Cell Lymphoma • Endocrine Disorders • Hematological Malignancies • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • PD-L1 • RHOA • SOCS1 • TNFAIP3

Multimodal therapy for primary ureteral small cell neuroendocrine carcinoma with high-grade urothelial component: case report and literature review. (PubMed, Front Urol) - "The patient received four cycles of neoadjuvant etoposide plus carboplatin chemotherapy, followed by radical left nephroureterectomy with bladder cuff excision. Adjuvant therapy included intravesical pirarubicin and six cycles of dual PD-1 blockade with toripalimab and vedicitumab...This case demonstrates the potential efficacy of integrating ICIs with standard treatment for advanced ureteral SCNEC. The durable response observed underscores the need for further research into early immunotherapy use and biomarker-guided therapeutic strategies."

IO biomarker • Journal • Endocrine Cancer • Genitourinary Neuroendocrine Carcinoma • Nephrology • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Pain • Solid Tumor • Urothelial Cancer • NCAM1 • SYP

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Xijing Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Clinical features analysis of inflammatory myofibroblastic tumors of the retroperitoneal and genitourinary system. (PubMed, BMC Urol) - "IMT can originate from any part of the genitourinary system, with pain being the most common symptom. Its clinical management is similar to that of malignant tumours of the genitourinary system, and complete surgical resection is the standard treatment strategy for all genitourinary IMT."

Journal • Genito-urinary Cancer • Oncology • Pain • Peritoneal Cancer • Solid Tumor

Association between HER2 overexpression and recurrence rate in patients with non-muscle-invasive bladder cancer following anthracycline-based intravesical instillation therapy (PubMed, Zhonghua Bing Li Xue Za Zhi) - "The impact of HER2 expression on the recurrence-free survival (RFS) of patients with intravesical anthracycline (epirubicin or pirarubicin) instillation after transurethral resection of bladder tumor (TURBT) was evaluated. In the patients treated with intravesical anthracycline instillation, HER2 high-expression was associated with a shorter RFS (P<0.001). HER2 high-expression seems to be not only associated with worse clinicopathological features of NMIBC but also a poor RFS in NMIBC patients treated with anthracycline instillation after TURBT."

Journal • Retrospective data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • HER-2

Pirarubicin determination with impedimetric and voltammetric DNA sensors based on poly(Nile Blue) electropolymerized from deep eutectic solvents. (PubMed, Analyst) - "For the impedimetric method, the limit of detection for pirarubicin was 50 pM for the coating from aqueous medium, and 0.1 fM and 0.05 fM for the coatings from reline and oxaline, respectively. The sensor based on the coating from reline showed the best analytical characteristics and reproducibility, enabling its use for the analysis of real samples."

Journal

Atractylodes macrocephala Koidz. Polysaccharide Alleviates Chemotherapy-Induced Depression-Like Behaviors Through the Gut-Brain Axis. (PubMed, Int J Mol Sci) - "Polysaccharide (AP) on pirarubicin chemotherapy-induced depression (CID) in breast cancer mice...More importantly, depletion of gut microbiota through antibiotics diminished the effectiveness of AP. Our results suggest that AP alleviates depression-like behaviors in chemotherapy-treated mice by regulating the gut microbiota and microbial metabolism, as well as suppressing ferroptosis in intestinal tissues."

Journal • Breast Cancer • CNS Disorders • Depression • Mood Disorders • Oncology • Psychiatry • Solid Tumor

RETRACTION: MiR-494-3p Aggravates Pirarubicin-Induced Cardiomyocyte Injury by Regulating MDM4/p53 Signaling Pathway. (PubMed, Environ Toxicol) - "Therefore, the article must be retracted. The authors did not respond to communications from the Publisher regarding the retraction."

Journal • MDM4 • MIR494

Synergistic Chemoimmunotherapy Using Pirarubicin-Loaded Tumor-Derived Extracellular Vesicles for Triple-Negative Breast Cancer (TNBC). (PubMed, Eur J Pharm Sci) - "In addition, compared with the control group, the tumor volume in the THP@TEVs group was reduced by approximately 62.1% (p<0.001, n=5) and no histopathological changes were observed in major organs (such as heart, liver, spleen, lungs, and kidneys) upon H&E staining. This study provides a precise, low-toxicity chemotherapy and immune synergistic strategy for TNBC and expands the potential of TEVs in tumor therapy."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CALR • CD8 • HMGB1

Multimodal Therapy for Primary Ureteral Small Cell Neuroendocrine Carcinoma with High-Grade Urothelial Component: Case Report and Literature Review (Frontiers) - "The patient received four cycles of neoadjuvant etoposide plus carboplatin chemotherapy, followed by radical left nephroureterectomy with bladder cuff excision. Adjuvant therapy included intravesical pirarubicin and six cycles of dual PD-1 blockade with toripalimab and vedicitumab. Post-neoadjuvant imaging showed a 60% reduction in tumor size. Pathology revealed R0 resection with marked tumor regression (Ki67 reduced to 40%). No recurrence was observed at 12-month follow-up."

Clinical data • Genitourinary Neuroendocrine Carcinoma • Urothelial Cancer

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Xijing Hospital

New P1 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Malignant Glomus Tumor of the Uterus With Cyclin D1 Expression and CARMN::NOTCH2 Fusion. (PubMed, Int J Gynecol Pathol) - "The patient underwent 4 courses of chemotherapy with ifosfamide and pirarubicin. The findings from this case highlight the morphologic and immunohistochemical features that are diagnostic of this rare uterine tumor. Furthermore, this report summarizes the morphologic criteria for malignancy and the key points for its differential diagnosis."

Journal • Gynecologic Cancers • Oncology • Solid Tumor • Uterine Cancer • CALD • CCND1 • NOTCH2 • SYP

Polymer Nanomedicines with pH-Triggered Pirarubicin Release: Revealing the Role of Carrier Hydrophilicity and Release Kinetics in Anticancer Performance. (PubMed, Biomacromolecules) - "Conjugates with aminohexanoyl linkers exhibited superior drug release and enhanced antitumor activity compared with those with shorter linkers. Overall, our study highlights that the rate of drug release, governed by the linker structure, plays a pivotal role in therapeutic efficacy, while the hydrophilicity of the polymer backbone has a lesser impact."

Journal • Oncology

Peach Gum Polysaccharide Prevents Chemotherapy-Induced Intestinal Injury and Degenerative Behavior. (PubMed, Integr Cancer Ther) - "Female C57BL/6 mice were injected with E0771 breast cancer cells and divided into 3 groups: control, chemotherapy (pirarubicin), and PGP treatment (pirarubicin plus PGP)...After the depletion of the intestinal flora, the antidepressant effect of PGP is significantly weakened. These findings suggest that PGP protects against chemotherapy-induced intestinal and behavioral damage by modulating the gut microbiota and gut-brain axis."

Journal • Breast Cancer • CNS Disorders • Depression • Oncology • Psychiatry • Solid Tumor

Hyaluronic acid as a treatment for refractory Bacillus Calmette-Guérin-induced cystitis: A narrative review. (PubMed, Bladder (San Franc)) - "Combination treatments with chondroitin sulfate or pirarubicin demonstrated superior outcomes compared to HA alone. While the studies reported minimal adverse effects, variability in study design, sample sizes, and follow-up durations limited the strength of the evidence. These findings suggest that HA can be safely administered to NMIBC patients alongside BCG therapy with minimal side effects and no adverse impact on treatment outcomes."

Journal • Review • Bladder Cancer • Genito-urinary Cancer • Infectious Disease • Oncology • Pain • Solid Tumor

Diffuse Large B-Cell Lymphoma with Cardiac Metastasis: A Case Report. (PubMed, Am J Case Rep) - "She was started on the standard R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). However, she developed severe bradycardia, necessitating regimen modification to R-CEOD (rituximab, cyclophosphamide, pirarubicin, etoposide)...Cardiac function was assessed by echocardiography and electrocardiogram and by assessing the levels of brain natriuretic peptide prior to treatment. During the process of treatment, the toxic effects of chemotherapeutic drugs, notably cardiac adverse reactions, were closely monitored and quickly treated."

Journal • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain

TACE combined with the intra-arterial infusion of bevacizumab for BCLC-stage B hepatocellular carcinoma beyond up-to-seven criteria: A prospective, single-arm, phase II study. (ASCO 2025) - P2 | "Patients were treated with TACE (30-40mg of pirarubicin, 30-40mg of lobaplatin, and lipiodol) plus Bevacizumab (15mg/kg, intra-arterial infusion, d1, Q3W) for four cycles, followed by maintenance therapy with Bevacizumab (15mg/kg, intravenously, d1, Q3W) to a maximum total cycle of eighteen unless any evidence of disease progression or unacceptable side effects. TACE combined with arterial infusion of bevacizumab in patients with BCLC-B stage HCC beyond up-to-seven criteria demonstrates promise as an effective treatment approach. Patient characteristics"

Clinical • P2 data • Hepatitis B • Hepatocellular Cancer • Hypertension • Infectious Disease • Oncology • Solid Tumor

The outcome of patients with peripheral T cell lymphoma treated with doxorubicin-based (CHOP) and pirarubicin-based regimen (THP-COP) regimen: a single institution experience. (PubMed, J Clin Exp Hematop) - "When stratified by treatment intensity, the CR rates in the dose-intensified group and the conventional dose group were 65% and 50% (P = 0.230), the 3-year EFS rates were 45.9% and 39.6% (P = 0.995), and the 3-year OS rates were 61.1% and 66.4% (P = 0.267), respectively. This study revealed no significant advantage of the THP-COP regimen over the CHOP regimen regarding treatment outcomes for newly diagnosed PTCLs."

Journal • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Primary adenocarcinoma of the renal pelvis: A case report. (PubMed, Medicine (Baltimore)) - "This case underscores the imperative for multimodal integration (surgery, chemotherapy, and ICIs) to optimize survival in advanced renal pelvic adenocarcinoma while highlighting the necessity of dynamic therapeutic adaptation-including regimen rechallenge and tyrosine kinase inhibitor combinations-to address recurrence and resistance. Proactive toxicity management (e.g., dose de-escalation for renal injury) and rigorous biomarker-driven surveillance (serial CA19-9 tracking with 3-month imaging) emerge as critical strategies to balance efficacy and safety in this aggressive malignancy."

IO biomarker • Journal • Acute Kidney Injury • Kidney Cancer • Nephrology • Oncology • Pain • Renal Calculi • Renal Cell Carcinoma • Renal Disease • Solid Tumor • CA 19-9

UPLC-Q-TOF-MS based investigation into the bioactive compounds and molecular mechanisms of Qishen Huanwu capsule attenuates anthracycline-induced cardiotoxicity. (PubMed, Phytomedicine) - "QSHWC alleviates anthracycline-induced cardiotoxicity by targeting cardiac pyroptosis through the PI3K/AKT pathway, while providing a multi-target therapeutic strategy."

Journal • Cardiovascular • Oncology • NLRP3

pH-Triggered delivery of pirarubicin-gemcitabine duo using polymeric nanoparticles for synergistic breast cancer therapy. (PubMed, Nanoscale Horiz) - "Both apoptotic analysis and cell proliferation inhibition studies revealed that the co-loaded nanoparticles exhibited a synergistic therapeutic effect across multiple breast cancer cell lines, surpassing the efficacy of Pira/Gem single drug-loaded nanoparticles and their free drug counterparts. These findings suggest that the Pira-Gem co-loaded nanoformulation holds considerable promise for breast cancer therapy and requires further exploration as a potential treatment strategy."

Journal • Breast Cancer • Oncology • Solid Tumor

Case series of adult Wilms' tumor and review of the literature. (PubMed, AME Case Rep) - "Two cases were treated with postoperative adjuvant chemotherapy (one case received the actinomycin D + vincristine regimen and pirarubicin + vincristine regimen; another case was treated with etoposide + carboplatin and cyclophosphamide + vincristine + adriamycin), and the other two cases were received postoperative follow-up only. AWT is a relatively rare malignant tumor with a low preoperative diagnostic accuracy and a poorer prognosis than children. Early diagnosis, successful surgery, and standardized postoperative adjuvant therapy according to pathological typing and staging are the key points to improve the survival of AWT patients."

Journal • Kidney Cancer • Oncology • Pain • Renal Cell Carcinoma • Solid Tumor • Urology • Wilms Tumor

TXB-001, A Newly-Developed Polymer-Conjugated Anthracycline, Alleviates Anthracycline-Induced Cardiotoxicity. (PubMed, Cardiovasc Toxicol) - "TXB-001 is a new candidate polymer-conjugated pirarubicin (THP) with higher THP purity and content compared to previous P-THP (polymerized THP) and is expected to exhibit lower cardiotoxicity and higher efficacy against cancer cells. We examined the effects of TXB-001 on cardiac function and the pharmacokinetics after its intravenous administration compared with those of existing anthracyclines (doxorubicin (DOX), DOXIL (liposomal formulation of DOX), THP) in mice...Collectively, these results suggest the potential of TXB-001 as an anti-cancer drug with fewer side effects than anthracyclines, particularly cardiotoxicity. Novel TXB-001 may become an effective anti-cancer drug with fewer cardiotoxicity."

Journal • Cardiovascular • Oncology